ANTX
Income statement / Annual
Last year (2023), AN2 Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, AN2 Therapeutics, Inc.'s net income was -$64.73 M.
See AN2 Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$77,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
-$77,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$54.87 M
|
$29.51 M
|
$16.91 M
|
$6.02 M
|
$4.89 M
|
| General & Administrative
Expenses |
$14.76 M
|
$12.75 M
|
$4.67 M
|
$1.27 M
|
$1.73 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$287,266.00
|
| Selling, General &
Administrative Expenses |
$14.76 M
|
$12.75 M
|
$4.67 M
|
$1.27 M
|
$289,000.00
|
| Other Expenses |
$0.00 |
-$45,000.00 |
-$38,000.00 |
-$6.32 M |
$0.00 |
| Operating Expenses |
$69.64 M |
$42.26 M |
$21.57 M |
$7.28 M |
$5.18 M |
| Cost And Expenses |
$69.64 M |
$42.26 M |
$21.57 M |
$7.28 M |
$5.18 M |
| Interest Income |
$0.00 |
$1.35 M |
$69,000.00 |
$3,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$514,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$69.64 M
|
$77,000.00
|
$21.57 M
|
$7.28 M
|
$31.07 M
|
| EBITDA |
$4.90 M
|
-$42.26 M
|
$0.00
|
-$6.32 M
|
$0.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$4.90 M
|
$1.31 M
|
$31,000.00
|
-$6.32 M
|
-$457,000.00
|
| Income Before Tax |
-$64.73 M |
-$40.96 M |
-$21.54 M |
-$13.60 M |
-$5.64 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$514,000.00 |
-$69,000.00 |
-$3,000.00 |
-$31,068.00 |
| Net Income |
-$64.73 M |
-$41.47 M |
-$21.47 M |
-$13.60 M |
-$5.64 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.74 |
-2.14 |
-1.15 |
-0.73 |
-0.3 |
| EPS Diluted |
-2.74 |
-2.14 |
-1.15 |
-0.73 |
-0.3 |
| Weighted Average Shares
Out |
$23.60 M
|
$19.40 M
|
$18.74 M
|
$18.74 M
|
$18.74 M
|
| Weighted Average Shares
Out Diluted |
$23.60 M
|
$19.40 M
|
$18.74 M
|
$18.74 M
|
$18.74 M
|
| Link |
|
|
|
|
|
